Skip to content
About

About

Lab image

about the company

Firebrick Pharma

Firebrick Pharma is an Australian pharmaceutical developer, which was founded in 2012 by Dr Peter Molloy and Dr Stephen Goodall with the mission to develop a nasal spray that killed all the germs (viruses or bacteria) responsible for respiratory infections, such as the common cold. After 9 years of development and testing, our first product is now in the final stages of development and is called Nasodine® Nasal Spray*

Nasodine Nasal Spray contains the broad-spectrum antimicrobial agent, povidone-iodine. In clinical studies, Nasodine has been shown to be well-tolerated as a four-times-daily nasal spray. Patents have been filed worldwide on its use as a treatment and preventative for the common cold.

If approved, Nasodine will be a first-in-class nasal spray medicine that targets the cause of colds, where they start in the nose.

 

*Nasodine Nasal Spray is not yet approved for sale in Australia.

 

THE FIREBRICK BREAKTHROUGH

In treating respiratory viral illnesses, such as the common cold, the challenge has always been that the infection of the nasal passages can be caused by any one of 200 or more viruses from at least six major groups. While 'rhinovirus' is responsible for most common cold infections, other groups of viruses can cause colds, including coronaviruses*, influenza virus, parainfluenza virus, RSV and metapneumovirus. In some cases, bacteria also can be responsible, including species of Haemophilus, Streptococcus and Moraxella.

The problem is that we rarely know the infectious culprit and some microorganisms can mutate. At Firebrick, we took an innovative approach, using a well-established broad-spectrum antimicrobial agent, called "povidone-iodine" that has been shown to rapidly inactivate (kill) the germs that can cause colds, and yet has been shown to be safe for nasal use (when used as directed). What’s more, because of its non-selective mode of action, it is virtually impossible for germs to develop resistance to it.

The new povidone-iodine nasal spray, called Nasodine® Nasal Spray, is designed to kill the germs (whether viruses or bacteria) that cause colds, in the nasal passages where the infection starts.

* These are seasonal coronavirus strains that cause cold symptoms, not to be confused with pandemic coronaviruses, such as SARS-CoV-2, which causes COVID-19. There is no published evidence that Nasodine® Nasal Spray can reduce the transmission risk or severity of COVID-19. 

six viruses

History

  • 2012

    Firebrick Pharma incorporated by Peter Molloy and Stephen Goodall with the mission to create a broad-spectrum antimicrobial nasal spray to treat the common cold.

  • 2013

    Product development commences.

  • 2014

    Australian patent filed.

  • 2015

    Australian patent granted and international patent filings commence. Formulation development commences in Melbourne laboratories.

  • 2016

    Series A funding closes; product development accelerates.

  • 2017

    Product formulation, packaging and manufacturing development completed; viral inactivation studies confirm activity.

  • 2018

    Safety testing models indicate product is safe for nasal use; new patents filed; Series B funding closes. Phase 1 and Phase 2 trials completed.

  • 2019

    Series C funding, Phase 3 trial completed, new patent filed.

  • 2020

    Series D (pre-IPO) funding closes; Australian registration dossier filed for Nasodine; new patents granted.

Firebrick BOARD AND MANAGEMENT

PLM 2021 HR Square LR

Peter Molloy

Founder & Executive Chairman, BSc, MBA, PhD

Peter Molloy is a qualified microbiologist and biochemist who built a successful career in the pharmaceutical industry, initially at Faulding (Aust) and then at Pharmacia (Pfizer), where he was Managing Director of Australia/NZ operations and later International Vice President for Strategic Marketing. During his career, he launched 23 new pharmaceutical products and executed 40 international licensing or distribution deals. Subsequently, he was CEO of four biotech companies in US and Australia, including two ASX-listed firms. As CEO of antiviral drug development company, Biota Holdings Limited (2002-2005), the company’s market value grew from $30m to around $300m. Subsequently, as founding CEO of Race Oncology (2016-2020), the company's market value grew from $12m to more than $400m during 2021. He obtained his BSc from University of Melbourne, his MBA from University of Adelaide, and he holds a PhD in biotechnology business. He is also a Fellow of the Australian Institute of Company Directors.

Selected SG 2021 LR

Stephen Goodall

Founder, Director & COO, BAppSc, MAppSc, MBA, PhD

Stephen Goodall has a successful track record in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He was instrumental in developing the intellectual property that underpins the Firebrick patent. Previously, he was Chief Operating Officer of Viralytics, which was later acquired in 2018 for $500 million by the US big pharma company, Merck. Prior to Viralytics, he was the Director of Pharmaceutical Development at Vapotronics, where he managed all aspects of inhaled drug development and formulation and before that, Director of Development at AGEN Biomedical. He is a founder of Firebrick and co-inventor on Firebrick patents. He has extensive experience in the preclinical, IND, regulatory and human clinical phases of drug development. He also has an impressive background in process development, production scale-up and GMP manufacturing for pharmaceuticals.

Phyllis

Professor Phyllis Gardner MD

Non Executive Director

Professor Phyllis Gardner is based in California and is a tenured Professor of Medicine at Stanford University; she is also on the Board of Fellows of Harvard Medical School. She obtained her Doctor of Medicine degree from Harvard Medical School, trained in internal medicine at Massachusetts General Hospital and completed research fellowships in Pharmacology at Columbia University and University College, London. After moving to Stanford in 1984, Phyllis was an active scientific researcher, with her expertise bridging medicine, pharmacology and drug delivery systems. After ten years in academia, she became interested in entrepreneurship, founding several biopharma ventures. From 1994 to 1998, she served as Principal Scientist and Head of Research at ALZA Corporation; and from 1999 to 2015, she was a partner at Essex Woodlands Health Ventures, a leading US venture capital firm focused on life sciences. She has been a director on numerous boards of US public biotech firms, including Aronex, Aerogen, Pharmacyclics, BioMarin, Corium, Revance and Cohbar.

Peter-Friedland-Firebrick

Professor Peter Friedland

Chief Medical Officer, MBBCh MMed FRACS FCS (SA)

Professor Peter Friedland is the Company’s Chief Medical Officer. Prof Friedland is an ENT (ear, nose and throat) specialist, associate professor at the University of Western Australia and professor at the University of Notre Dame, Fremantle. He holds several national appointments including memberships of the board of the Australian Society of Otorhinolaryngology Head & Neck Surgery at Royal Australian College of Surgeons (RACS), the Panel of Clinical Experts for the Australian Government Department of Health and the MBS (Medical Benefit Schemes) National ENT Taskforce. Prof Friedland, a surgeon scientist at Sir Charles Gairdner hospital and Joondalup Health Campus. He is currently engaged in multidisciplinary clinical research in head and neck cancer, hearing loss rehabilitation and nasal disease. In the last decade, he has published more than 50 peer reviewed scientific articles and delivered more than 150 conference presentations and invited lectures. Prior to immigrating to Australia in 2009, he was clinical head of the ENT department at the University of Witwatersrand, Donald Gordon Medical Centre, Johannesburg, South Africa. Prof Friedland was appointed Mr. Nelson Mandela’s ENT specialist from 2000 to 2009.

Simon-Tucker-pp

Simon Tucker

Chief Scientific Officer, BSc (Hons), PhD

Dr Simon Tucker is a virologist with decades of pharmaceutical R&D management experience.  He previously led teams at GD Searle (US) focused on new antivirals including influenza and HIV, where he was a member of the team responsible for the discovery of the HIV protease inhibitor, amprenavir.  He subsequently led the Gene Therapy Group at the University of Glasgow (UK), before joining Biota Pharmaceuticals, the world-leading antiviral drug developer at the time.  As Vice President of Research at Biota he oversaw the research and IP portfolios, managed the R&D strategy and execution, and was directly involved in multiple licensing deals, collaborative projects with major pharmaceutical companies and the discovery and progression of clinical candidates.  He led the teams that discovered zanamivir (Relenza), the world’s first neuraminidase inhibitor for treatment of influenza, as well as the world’s first point of care diagnostic test for influenza A and B. He also presided over the discovery and development of candidate drugs for the common cold (vapendavir), RSV and hepatitis C .  He is a founder & former CEO at 360biolabs and is currently Chairman of Jumpstart-Fertility, an international biotech focused on drugs to address female infertility.

Robyn

Robyn Branigan

Head of Marketing

Robyn Branigan is an accomplished marketing professional with over 12 years’ experience developed across a diverse portfolio of high-profile brands and categories. Robyn has a Bachelor of Commerce (Marketing) degree from The University of Melbourne and a Master of Advertising from RMIT University. Previously, Robyn worked in marketing for Nintendo Australia with accountability for the Wii Brand, then was a brand manager at Kraft Foods working in the Cadbury Seasonal Team before joining Swisse Wellness, a leading Australian brand in the Vitamins and Supplements category. At Swisse, Robyn spent over 8 years progressing through a number of roles including Senior Marketing Manager (Brand Communications). During this period, Swisse experienced significant growth and progression from a privately owned business to a global wellness brand within the portfolio of the H&H Group, listed on the Hong Kong Stock Exchange.

Liling-Xie

Liling Xie

Head of Regulatory Affairs, BChE, MAppSc

Liling Xie is the Head of Regulatory Affairs at Firebrick Pharma. She has more than 16 years’ regulatory experience with a successful track record in the registration of Injectable and Generic medicines. She possesses solid analytical chemistry experience in pharmaceutical product development. Prior to joining Firebrick, Liling was Regulatory Affairs Manager at Hospira (Mayne Pharma) responsible for Australia, New Zealand, and Greater China regions. She is also a long term consultant to Biological Therapies. In addition to her pharmaceutical background, she worked for a renowned food processing and sales company in China as Vice President, responsible for multiple plants and company logistics. She played an instrumental role in raising capital funds and executed international deals for the company.